ArticleBreast cancer : basic and clinical research2025
Evaluation of the Prognostic Value of Obesity, Vitamin D Concentrations, and Systemic Inflammatory Response Indexes (SIRI, SII, PIV) in Patients With Breast Cancer Scheduled for Neoadjuvant Treatment.
Article in Breast cancer : basic and clinical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- PIV, PNI and HALP score for predicting pathological complete response in breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
- Potential Diagnostic and Prognostic Value of Neutrophil Counts, Neutrophil-Lymphocyte Ratio, Pan-Immunoinflammatory Score, Systemic Immunoinflammatory Index, and Systemic Inflammatory Response Index in Brain Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical and pathological indicators for predicting disease-free survival after radical surgery in elderly patients with early-stage triple-negative invasive ductal carcinoma of the breast.Frontiers in oncology · 2026Article
- Modified systemic immune-inflammatory index, modified systemic inflammatory response index and hemoglobin-albumin-lymphocyte-platelet score may serve as markers for evaluating the efficacy of neoadjuvant therapy in breast cancer patients.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The purpose of this study was to determine the prognostic utility of vitamin D concentrations and BMI (body mass index) values and the systemic immune-inflammation index (SII), the systemic inflammation response index (SIRI) and the pan-immune-inflammation value (PIV) to predict the achievement of a complete response to neoadjuvant treatment (NAT) in patients with breast cancer. The correlations between systemic inflammatory response indices and vitamin D concentrations and BMI values were also analysed. Material and Methods: The study included 96 patients with breast cancer, prior to the start of NAT, of which 51 patients were diagnosed with triple-negative breast cancer (TNBC) and 45 patients with human epidermal growth factor receptor type 2 (HER2)-positive type. Results: The SIRI and PIV indices were shown to be significantly higher in patients with TNBC ( Conclusions: In patients with breast cancer, high SIRI and PIV values may indicate the biological subtype of TNBC. In the HER2+ group, higher SII values were associated with low vitamin D concentrations and elevated BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.